Safety of the combination of lapatinib (L) plus trastuzumab (T) in patients (pts) with HER2-Positive (+) metastatic breast cancer (MBC)

被引：0
|
作者：
Storniolo, A. [1 ]
Koehler, M. [2 ]
Preston, A. [2 ]
Rappold, E. [2 ]
Byrne, J. [2 ]
Stein, S. [2 ]
Ewer, M. [3 ]
机构：
[1] Indiana Univ, Med Ctr, Indianapolis, IN USA
[2] GlaxoSmithKline Inc, Oncol Med Dev Ctr, Collegeville, PA USA
[3] MD Anderson Canc Ctr, Houston, TX USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70771-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：187 / 187
页数：1
相关论文
共 50 条
  • [1] Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC).
    Salvador, Javier
    Ruiz Borrego, Manuel
    Valero, Maria
    Bayo, Juan L.
    De La Cruz-Merino, Luis
    Carabantes, FRancisco
    Rodriguez de la Borbolla, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).
    Freixinos, V.
    Sanchez-Olle, G.
    De Mattos-Arruda, L.
    Di Cosimo, S.
    Saura, C.
    Gomez, P.
    Perez-Garcia, J. M.
    Cortes, J.
    Baselga, J.
    Bellet, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] TRASTYVERE study: A retrospective analysis of HER2-positive metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T)
    Gavila, Joaquin
    Bermejo, Begona
    Rodriguez-Lescure, Alvaro
    Lao Romera, Juan
    Manso, Luis
    Brunet, Joan
    Munoz, Eva
    Santisteban, Marta
    Rodriguez, Cesar A.
    Santaballa, Ana
    de la Haba, Juan
    Sanchez-Rovira, Pedro
    Ruiz-Borrego, Manuel
    Angel Garcia-Saenz, Jose
    Cortes, Javier
    Llombart, Antonio
    CANCER RESEARCH, 2015, 75
  • [5] Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.
    Gori, S.
    Montemurro, F.
    Spazzapan, S.
    Metro, G.
    Foglietta, J.
    Bisagni, G.
    Ferzi, A.
    Silva, R. R.
    Gamucci, T.
    Clavarezza, M.
    Stocchi, L.
    Fabi, A.
    Cognetti, F.
    Torrisi, E.
    Crivellari, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Cardiac safety in patients (pts) with metastatic breast cancer (MBC) treated with lapatinib (L) and trastuzumab (TRA)
    Storniolo, A. M.
    Koehler, M.
    Preston, A.
    Rappold, E.
    Byrne, J.
    Ewer, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] MOLECULAR PREDICTORS FOR PRIMARY RESISTANCE TO TRASTUZUMAB IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC) PATIENTS (PTS)
    Landi, L.
    Marchetti, A.
    Fabi, A.
    Mottolese, M.
    Destro, A.
    Fabiani, S.
    Cappuzzo, F.
    Varella-Garcia, M.
    Roncalli, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 39 - 39
  • [8] Preliminary results from TRASTYVERE study: A retrospective analysis of HER2-positive (HER2) metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T).
    Gavila, Joaquin
    Bermejo, Begona
    Manso, Luis
    Munoz, Eva
    Anton, Antonio
    Brunet, Joan
    Rodriguez-Lescure, Alvaro
    Augusto Rodriguez, Cesar
    Santaballa, Ana
    Sanchez-Rovira, Pedro
    de la Haba-Rodriguez, Juan
    Santisteban, Marta
    Ruiz Borrego, Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC)
    Lin, N. U.
    Mayer, I. A.
    Najita, J. S.
    Hobday, T. J.
    Falkson, C. I.
    Dees, E. C.
    Rimawi, M. F.
    Nanda, R.
    Gelman, R. S.
    Josephs, K.
    Richardson, A.
    Flores, L.
    Van Den Abbeele, A. D.
    Yap, J. T.
    Arteaga, C. L.
    Wolff, A. C.
    Krop, I. E.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC)
    Lin, N. U.
    Mayer, I. A.
    Hobday, T. J.
    Falkson, C. I.
    Dees, E. C.
    Nanda, R.
    Krop, I. E.
    Rimawi, M. F.
    Wolff, A. C.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345